Physostigmine Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the use of physostigmine during breastfeeding.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information in nursing mothers was not found as of the revision date. In animals, cholinergic drugs increase oxytocin release,[1] and physostigmine increases serum prolactin in humans.[2,3] The prolactin level in a mother with established lactation may not affect her ability to breastfeed.
References
1.
Clarke G, Fall CH, Lincoln DW, et al. Effects of cholinoceptor antagonists on the suckling-induced and experimentally evoked release of oxytocin. Br J Pharmacol. 1978;63:519–27. [PMC free article: PMC1668097] [PubMed: 566601]
2.
Risch SC, Janowsky DS, Siever LJ, et al. Cholinomimetic-induced co-release of prolactin and beta-endorphin in man. Psychopharmacol Bull. 1982;18:21–5. [PubMed: 6296908]
3.
Risch SC, Janowsky DS, Siever LJ, et al. Correlated cholinomimetic-stimulated beta-endorphin and prolactin release in humans. Peptides. 1982;3:319–22. [PubMed: 6289276]
Substance Identification
Substance Name
Physostigmine
CAS Registry Number
57-47-6
Drug Class
Breast Feeding
Lactation
Cholinesterase Inhibitors
Parasympathomimetics
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
